NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EnGeneIC

EnGeneIC

Private
SydneyHealthcare & Life Scienceshttps://engeneic.com/

Last Round

Crowdfunding

Aug 1, 2021

Total Funding Raised

$17.17M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EnGeneIC is a clinical-stage biopharmaceutical company that has developed a proprietary nanocell technology for the targeted delivery of chemotherapeutics and functional nucleic acids for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

nanocell technologytargeted cancer therapydrug delivery platformtargeted drug deliveryimmunotherapynanomedicinecancer nanomedicinecyto-immunotherapybacterially-derived nanocellsdrug delivery vehiclepancreatic cancersolid tumor therapybiologic drug deliveryArmed Nanocell Drug ConjugateANDCsiRNA deliverytheranosticsglioblastoma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EnGeneIC Comps

Public and private peers based on sector, stage, and business model.

EnGeneIC comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

EnGeneIC Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingAug 1, 2021
Series BJan 6, 2015

Key People

Founding team and executive leadership

Jennifer MacDiarmid

Joint-CEO And Director

Executive Team

EnGeneIC Investors

Notable investors and investment history

EnGeneIC investors
InvestorRounds
GRT Capital PartnersSeries B
Foley & Lardner LLPSeries B
VentureCrowdCrowdfunding

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 70% MoM.

  • Oct 13, 2025

    Grew 18% QoQ, from 44 to 52 employees.

EnGeneIC Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EnGeneIC Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EnGeneIC's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney
Employee Range55
Year Founded2001
Last FundingAug 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.